GH Research (NASDAQ:GHRS) Shares Gap Down to $21.14

GH Research PLC (NASDAQ:GHRS)’s share price gapped down before the market opened on Monday . The stock had previously closed at $21.14, but opened at $19.69. GH Research shares last traded at $19.69, with a volume of 100 shares changing hands.

Several equities analysts have recently commented on GHRS shares. Cowen started coverage on shares of GH Research in a report on Tuesday, July 20th. They set an “outperform” rating and a $17.25 price target on the stock. Canaccord Genuity began coverage on shares of GH Research in a report on Tuesday, July 20th. They set a “buy” rating and a $35.00 price target on the stock. Stifel Nicolaus began coverage on shares of GH Research in a research note on Tuesday, July 20th. They issued a “buy” rating and a $26.00 price objective for the company. Finally, JMP Securities began coverage on shares of GH Research in a research note on Tuesday, July 20th. They issued an “outperform” rating and a $35.00 price objective for the company.

The firm’s 50 day simple moving average is $20.26.

Institutional investors have recently added to or reduced their stakes in the business. Qube Research & Technologies Ltd acquired a new position in GH Research during the 2nd quarter worth $381,000. Squarepoint Ops LLC acquired a new position in GH Research during the 2nd quarter worth $391,000. Millennium Management LLC acquired a new position in GH Research during the 2nd quarter worth $997,000. Pinz Capital Management LP acquired a new position in GH Research during the 2nd quarter worth $1,489,000. Finally, Walleye Capital LLC acquired a new position in GH Research during the 2nd quarter worth $1,849,000. 54.62% of the stock is owned by hedge funds and other institutional investors.

GH Research Company Profile (NASDAQ:GHRS)

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

Further Reading: Day Trading

Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.